A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast

Andrea Chiricozzi, Dante Caposiena, Virginia Garofalo, Maria Vittoria Cannizzaro, Sergio Chimenti, Rosita Saraceno

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show some limits in terms of tolerability and route of administration. Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways. Because of the favorable safety profile and the oral route of administration, apremilast may represent a promising therapeutic target for moderate-to-severe psoriasis. In this review, we report an updated overview about clinical trials testing apremilast in the treatment of psoriasis and seek to provide comprehensive information about this anti-psoriatic drug and a future perspective of the therapeutic algorithm for psoriasis.
Lingua originaleEnglish
pagine (da-a)237-249
Numero di pagine13
RivistaExpert Review of Clinical Immunology
Stato di pubblicazionePubblicato - 2016


  • Psoriasis
  • apremilast
  • oral drug
  • otezla
  • phosphodiesterase inhibitor
  • small molecule


Entra nei temi di ricerca di 'A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast'. Insieme formano una fingerprint unica.

Cita questo